Norwegian 'Oslo Patient' Achieves HIV Remission Following Stem Cell Transplant with Rare Genetic Mutation
核心洞察
A 63-year-old Norwegian man known as the "Oslo patient" has become the 10th person worldwide to achieve long-term HIV (搜索) remission after receiving a stem cell transplant from his brother who carried a rare CCR5 (搜索)-delta 32 genetic mutation.
The patient stopped antiretroviral therapy (搜索) two years post-transplant and remains free of detectable HIV (搜索) DNA in blood, gut, and bone marrow samples five years after the procedure.
While the case provides valuable insights for HIV (搜索) cure research, bone marrow transplants carry significant risks with 10-20% mortality rates within one year, making them unsuitable as a widespread treatment option.
A 63-year-old Norwegian man has achieved long-term HIV (搜索) remission following a stem cell transplant from his brother, becoming only the 10th person worldwide to reach this milestone. The case, published in Nature Microbiology, offers new insights into potential HIV cure strategies while highlighting the complex relationship between immune system replacement and viral elimination.
Patient Background and Treatment Journey
The Oslo patient was diagnosed with HIV (搜索) in 2006 and began antiretroviral therapy (搜索) in 2010, achieving undetectable viral status. In 2017, he developed fatigue and a sharp drop in blood cell counts, leading to a 2018 diagnosis of myelodysplastic syndrome (搜索), a form of bone marrow cancer (搜索). After initially responding to treatment but subsequently relapsing, doctors pursued a bone marrow transplant to replace his diseased cells.
His brother served as the donor, and medical teams at Oslo University Hospital (搜索) discovered that the donor's stem cells carried a rare genetic mutation known as CCR5 (搜索)-delta 32. This mutation disables the CCR5 receptor on immune cells that HIV (搜索) normally uses as its entry point, effectively making the immune system impervious to HIV infection.
Transplant Outcomes and Viral Clearance
The allogeneic hematopoietic stem cell transplantation (HSCT) achieved remarkable results over a five-year monitoring period. Analyses of blood, gut, and bone marrow samples showed that "full donor chimerism" had been achieved, meaning nearly 100% of the patient's blood-forming and immune cells were derived from the HIV (搜索)-resistant stem cells.
Four years after the transplant, all traces of functioning HIV (搜索) DNA were cleared from the treated individual. The patient was able to stop HIV medication two years after the HSCT, with no evidence of viral rebound at the five-year follow-up. Researchers found no virus capable of replicating, no immune response targeting HIV, and a decline in HIV-specific antibodies over time.
Immune System Transformation
The research team observed significant changes in the patient's immune response to HIV (搜索). T cells stopped responding to the HIV threat, and HIV antibodies declined over time. As the researchers noted, "The absence of HIV-specific T cell responses in our data supports the hypothesis that such an absence correlates with sustained HIV remission."
What makes this case particularly notable is that the gut was extensively tested and marked clear of functioning HIV (搜索) DNA. The gut is where HIV most likes to lurk in its dormant state, ready to emerge again when treatment is discontinued.
Clinical Challenges and Complications
Despite the successful outcome, the patient experienced severe complications during treatment. He developed graft-versus-host disease (搜索), a serious condition where the body attacks transplanted cells as foreign. The patient was treated with immune-modulating medication and ultimately recovered, though this immune system reaction and the drugs used to treat it may have been partially responsible for HIV (搜索) being almost entirely wiped out.
Study author Marius Trøseid told Live Science that the patient "feels like he has won the lottery twice." He was cured of his bone marrow disease, which could be fatal, and is also now likely cured of HIV (搜索).
Limitations and Future Implications
While encouraging, bone marrow stem cell transplants are not a viable option for widespread HIV (搜索) treatment. These procedures are risky reboots of the immune system that leave patients vulnerable to infection and are performed only as a last resort. Research indicates that 10-20% of patients who undergo these transplants die within a year, regardless of the underlying condition being treated.
The researchers emphasize that their findings contribute valuable evidence to the existing knowledge base regarding HIV (搜索) cure cases. "Moreover, this and other studies on HIV cure enhance our understanding of HIV pathology, molecular mechanisms, and predictive biomarkers that may be of broader interest, extending beyond patients treated with allogeneic HSCT," they write.
Research Directions
The team plans to analyze data from all rare 'cure' cases documented so far to better understand what these patients can reveal about defeating HIV (搜索). "Moving forward, a critical step will be to compare existing cases of HIV cure to identify the most effective combination of biomarkers," the researchers state. "Conducting individual patient data meta-analyses is a logical next step, ideally followed by prospective sampling and new analyses that apply harmonized protocols in centralized laboratories."
With nearly 41 million people worldwide living with HIV (搜索) as of 2024, according to the World Health Organization, these rare cases provide crucial insights that could guide the development of more accessible treatments for achieving HIV remission or cure.